According to the 2021 statistics and the US census, about 7.7 million women in the general population were diagnosed with HPV—the human papillomavirus, and the primary cause of cervical cancer.
The traditional means of detection is the pap smear, which has a sensitivity and specificity of 47.19% and 82.2%, respectively.
Curiva™, however, seeks to transform and create a paradigm shift regarding detection and, in the process, reposition the global discussion on women’s healthcare.
Curiva™ is working to reduce the rate of cervical cancer by delivering a faster, more accurate diagnosis through a non-invasive, wearable diagnostic patch that replaces the Pap Smear and colposcopy. Focused on the patient, Curiva™’s flagship product, the diaPatch™, delivers same-day results while reducing diagnostic costs for healthcare providers, health systems, and payers.
The microneedle-mediated diagnostic patch, diaPatch™, will detect the early onset of cervical cancer through a process that lasts about 30 minutes, the equivalent length of a typical visit to a doctor’s office.
“We believe our product, diaPatch™ can impact the ways in which cervical cancer prevention is currently being addressed by significantly transforming the lives of the more than 300,000 women worldwide dying from the disease” Curiva™ founder Eydis Lima told Forbes, which recognized the company in its article, “Meet 7 Femtech Companies Innovating In The Area Of Ovarian Health, Breast And Gynecological Cancers.”
diaPatch™ allows healthcare professionals—and patients—to test quickly for biomarkers that flag cervical cancer sooner.
diaPatch™ is paired with a data service and companion app, the ELLEApp™, which allows for real-time results monitoring and enhanced patient/provider engagement. The ELLEApp™ streamlines physician workflows and enhances the ease of referrals; while raising patient awareness, allowing for real-time monitoring which therefore encourages stricter compliance. 
As detailed in the Forbes article, other interviews and panels, Eydis was inspired to launch Curiva™ while researching ovarian cancer at Yale University, following her participation in a 2016 Yale Health Hackathon. Eydis shared the frustration that compounded the uncertainty facing patients she observed at Yale-New Haven-Smilow Cancer Hospital, in the waiting areas and operating rooms. Eydis took it upon herself to ease the burden of the patients and their families by creating a new solution to improve women’s health.
“As an entrepreneur, I seek to contribute to the medical world by innovating for patients and creating new products,” said Eydis, who holds a Bachelor of Science Degree in Chemical Engineering from the University of Massachusetts—Amherst; and a Master of Science Degree in Entrepreneurship from the University of Notre Dame. “To succeed and generate an impact, the development and evolution of healthcare tools must include and rely on the voice of all stakeholders—the physicians and the patients.”
To learn more about Curiva™, visit curiva.co.
